ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial tests if adding one drug helps patients live longer
Disease control Recruiting nowThis large, late-stage trial is testing which of two chemotherapy combinations works better for people with advanced stomach or esophageal cancer that has spread and cannot be removed by surgery. About 382 participants will be randomly assigned to receive either the standard two-…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat cancers: adding immune booster to standard care
Disease control Recruiting nowThis study is for people with advanced stomach or esophageal cancer that has worsened after initial treatment. It tests if adding an immunotherapy drug called nivolumab to the standard two-drug chemotherapy helps control the cancer better and helps patients live longer. About 224…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists test 'One-Two Punch' against Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have a specific marker called HER2. The treatment pairs an existing targeted cancer drug with a new pill that aims to block cancer cells' ability to…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug duo tested for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help control advanced stomach or gastroesophageal cancers that have spread or cannot be surgically removed. The trial is for adults whose cancer has continued to grow despite…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC